{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:36:46Z","timestamp":1747183006073,"version":"3.40.5"},"reference-count":67,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The advent of systemic therapies with high intracranial efficacy in recent years is changing the therapeutic paradigm and renewing interest in the management of central nervous system (CNS) and leptomeningeal metastases from solid organ tumors. CNS metastases have traditionally heralded a dismal prognosis with median survival of 3\u201310 months, and were primarily treated with local therapeutic modalities, such as surgery or radiation therapy. Although these modalities still have a role in the management of CNS disease, newer agents, such as small molecule tyrosine kinase inhibitors and immune\u2010checkpoint inhibitors, are now paving the way as an alternative therapeutic option for those with oligometastatic or low\u2010volume intracranial disease, potentially eliminating or delaying the need for local treatment modalities in this setting. Herein, we summarize the systemic treatments with proven intracranial efficacy, currently approved for use in Australia for advanced mutation\u2010driven non\u2010small cell lung cancer, melanoma, and breast cancer, as well as novel agents in preclinical and clinical trial development.<\/jats:p>","DOI":"10.1111\/ajco.13759","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T08:30:44Z","timestamp":1646296244000},"page":"515-525","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The systemic management of central nervous system metastases and leptomeningeal disease from advanced lung, melanoma, and breast cancer with molecular drivers: An Australian perspective"],"prefix":"10.1111","volume":"18","author":[{"given":"Clare","family":"Senko","sequence":"first","affiliation":[{"name":"Olivia Newton\u2010John Cancer Wellness and Research Centre Austin Hospital  Melbourne Victoria Australia"},{"name":"La Trobe University School of Molecular Sciences  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashray","family":"Gunjur","sequence":"additional","affiliation":[{"name":"Olivia Newton\u2010John Cancer Wellness and Research Centre Austin Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adithya","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Olivia Newton\u2010John Cancer Wellness and Research Centre Austin Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui K.","family":"Gan","sequence":"additional","affiliation":[{"name":"Olivia Newton\u2010John Cancer Wellness and Research Centre Austin Hospital  Melbourne Victoria Australia"},{"name":"La Trobe University School of Cancer Medicine  Melbourne Victoria Australia"},{"name":"Department of Medicine University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3891-2489","authenticated-orcid":false,"given":"Sagun","family":"Parakh","sequence":"additional","affiliation":[{"name":"Olivia Newton\u2010John Cancer Wellness and Research Centre Austin Hospital  Melbourne Victoria Australia"},{"name":"La Trobe University School of Cancer Medicine  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Cher","sequence":"additional","affiliation":[{"name":"Olivia Newton\u2010John Cancer Wellness and Research Centre Austin Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.07.012"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-011-0203-y"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30911"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_241345"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now197"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-010-0128-6"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9363"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9597"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70057-4"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.017"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.12.011"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)30565\u20102"},{"issue":"5","key":"e_1_2_8_16_1","first-page":"437","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase\u2010positive non\u2010small\u2010cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou C","year":"2019","journal-title":"Lancet"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00505"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00702-4"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2282"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081966"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30680-0"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa052"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30655-2"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.8501"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30429-1"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32547"},{"key":"e_1_2_8_28_1","unstructured":"Phase II Study of Cobimetinib in Combination with Vemurafenib in Active Melanoma Brain Metastases (coBRIM\u2010B) [last updated Oct 12 2017]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2014. Available from:clinicaltrials.gov\/ct2\/show\/NCT02230306."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000491"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz255.001"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01414"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920953729"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32937"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu133"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02822"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.020"},{"issue":"5","key":"e_1_2_8_38_1","first-page":"S1283","article-title":"LBA1 \u2013 trastuzumab deruxtecan (T\u2010DXd) vs trastuzumab emtansine (T\u2010DM1) in patients (Pts) with Her2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY\u2010Breast03 study","volume":"32","author":"Cortes J","year":"2021","journal-title":"Ann Oncol"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70432-1"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-015-0082-6"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.011.10315"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2016.12.02"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051115"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10275-0"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30556\u20108"},{"key":"e_1_2_8_46_1","unstructured":"A Study of Amivantamab a Human Bispecific EGFR and cMet Antibody in Participants with Advanced Non\u2010Small Cell Lung Cancer (CHRYSALIS) [last updated May 18 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2015. Available from:clinicaltrials.gov\/ct2\/show\/NCT02609776."},{"key":"e_1_2_8_47_1","unstructured":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non\u2010Small Cell Lung Cancer (MARIPOSA) [last updated Feb 5 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2020. Available from:clinicaltrials.gov\/ct2\/show\/NCT04487080."},{"key":"e_1_2_8_48_1","unstructured":"A Study of Repotrectinib (TPX\u20100005) in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1\u20103 Rearrangements (TRIDENT\u20101) [last updated Feb 1 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2017. Available from:clinicaltrials.gov\/ct2\/show\/NCT03093116."},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103695"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002787"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004407"},{"key":"e_1_2_8_53_1","unstructured":"Nivolumab with Trametinib and Dabrafenib in Treating Patients with BRAF Mutated Metastatic or Unresectable Stage III\u2013IV Melanoma (TRIDeNT) [last updated April 5 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2016. Available from:clinicaltrials.gov\/ct2\/show\/NCT02910700."},{"key":"e_1_2_8_54_1","unstructured":"A Study of Tucatinib vs. Placebo in Combination with Capecitabine & Trastuzumab in Patients with Advanced Her2+ Breast Cancer (HER2CLIMB) [last updated Sept 28 2020]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2015. Available from:clinicaltrials.gov\/ct2\/show\/NCT02614794."},{"key":"e_1_2_8_55_1","unstructured":"A Study of Osimertinib with or without Chemotherapy as 1st Line Treatment in Patients with Mutated Epidermal Growth Factor Receptor Non\u2010Small Cell Lung Cancer (FLAURA2) [last updated March 1 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2019. Available from:clinicaltrials.gov\/ct2\/show\/NCT04035485."},{"key":"e_1_2_8_56_1","unstructured":"A Randomised Phase II Trial of Osimertinib with or without SRS for EGFR Mutated NSCLC with Brain Metastases (OUTRUN) [last updated Mar 9 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2018. Available from:clinicaltrials.gov\/ct2\/show\/NCT03497767."},{"key":"e_1_2_8_57_1","unstructured":"Assessing an Oral EGFR Inhibitor DZD9008 in Patients Who Have Advanced Non\u2010Small Cell Lung Cancer with EGFR or HER2 Mutation (WU\u2010KONG1) [last updated April 9 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2019. Available from:clinicaltrials.gov\/ct2\/show\/NCT03974022."},{"key":"e_1_2_8_58_1","unstructured":"A Study of the Anti\u2010PD1 Antibody PDR001 in Combination with Dabrafenib and Trametinib in Advanced Melanoma (COMBI\u2010i) [last updated April 14 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2016. Available from:clinicaltrials.gov\/ct2\/show\/NCT02967692."},{"key":"e_1_2_8_59_1","unstructured":"A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation\u2010Positive Patients with Metastatic or Unresectable Locally Advanced Melanoma (TRILOGY) [last updated Nov 19 2020]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2016. Available from:clinicaltrials.gov\/ct2\/show\/NCT02908672."},{"key":"e_1_2_8_60_1","unstructured":"Anti\u2010PD1 Brain Collaboration and Radiotherapy Extension (ABC\u2010X Study) (ABC\u2010X) [last updated Jun 9 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2017. Available from:clinicaltrials.gov\/ct2\/show\/NCT03340129."},{"key":"e_1_2_8_61_1","unstructured":"Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non\u2010Small Cell Lung Cancer [last updated Aug 3 2020]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2016. Available from:clinicaltrials.gov\/ct2\/show\/NCT02681549."},{"key":"e_1_2_8_62_1","unstructured":"Bevacizumab and Atezolizumab with or without Cobimetinib in Treating Patients with Untreated Melanoma Brain Metastases [last updated Jun 11 2020]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2017. Available from:clinicaltrials.gov\/ct2\/show\/NCT03175432."},{"key":"e_1_2_8_63_1","unstructured":"An Open\u2010Label Randomised Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard\u2010Dose and High\u2010Dose Regimen in Patients with BRAFV600\u2010Mutant Melanoma Brain Metastasis (POLARIS) [last updated May 6 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2019. Available from:clinicaltrials.gov\/ct2\/show\/NCT03911869."},{"key":"e_1_2_8_64_1","unstructured":"A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild\u2010Type Melanoma with Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation\u2010Positive Melanoma with Central Nervous System Metastases [last updated May 18 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2018. Available from:clinicaltrials.gov\/ct2\/show\/NCT03625141."},{"key":"e_1_2_8_65_1","unstructured":"A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF\u2010V600 Mutant Melanoma with Brain Metastases [last updated May 13 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2020. Available from:clinicaltrials.gov\/ct2\/show\/NCT04511013."},{"key":"e_1_2_8_66_1","unstructured":"Stereotactic Radiosurgery Added to Binimetinib and Encorafenib in Patients with BRAFV600 Melanoma with Brain Metastasis (BECOME\u2010MB) [last updated Feb 23 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2020. Available from:clinicaltrials.gov\/ct2\/show\/NCT04074096."},{"key":"e_1_2_8_67_1","unstructured":"HKI\u2010272 for Her2\u2010Positive Breast Cancer and Brain Metastases [last updated May 21 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2011. Available from:clinicaltrials.gov\/ct2\/show\/NCT01494662."},{"key":"e_1_2_8_68_1","unstructured":"Basket Study of Neratinib in Participants with Solid Tumors Harboring Somatic Her2 or EGFR Exon 18 Mutations (SUMMIT) [last updated May 19 2021]. In: Clinical Trials.gov [Internet]. U.S. National Library of Medicine;2013. Available from:clinicaltrials.gov\/ct2\/show\/NCT01953926."}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13759","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13759","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:22:34Z","timestamp":1692649354000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/ajco.13759"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13759","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"type":"print","value":"1743-7555"},{"type":"electronic","value":"1743-7563"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"2021-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}